Search Results 571-580 of 16531 for Strontium-89

  1. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  2. Clinical trials - Oncology (Medical)

    Mayo Clinic Oncology — Medical oncologists at Mayo Clinic offer innovative treatments for cancers of the organs, bones, muscles and connective tissues.

  3. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  4. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  5. Clinical trials - Oncology (Medical)

    Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...

  6. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  7. Clinical trials - Oncology (Medical)

    Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by ...

  8. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  9. Bone cancer - Doctors and departments - Mayo Clinic

    Bone cancer most commonly affects the long bones in the arms and legs. Some types happen mostly in children, while others affect mostly adults.

  10. Clinical trials - Oncology (Medical)

    In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's ...